We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As the United States and world continue to struggle with the ongoing effects of the COVID-19 pandemic, TRICCAR, Inc. (OTC: FOSI), announces the results of a double-blind placebo-controlled study of AVL™.